EP Patent

EP3102604B1 — Combination of a pd-1 antagonist and a 4-1bb agonist for treating cancer

Assigned to Organon Pharma UK Ltd · Expires 2020-01-15 · 6y expired

What this patent protects

Patent listed against lenvatinib-mesylate.

Drugs covered by this patent

Patent Metadata

Patent number
EP3102604B1
Jurisdiction
EP
Classification
—
Expires
2020-01-15
Drug substance claim
No
Drug product claim
No
Assignee
Organon Pharma UK Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.